The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease
Open accessAbstract
4,500 mild-moderate AD patients randomized to placebo and 0.5mg/kg i.v.every 13 weeks for 18 months in APOE4 carriers, and randomized to placebo, 0.5, 1.0mg/kg i.v.every 13 weeks for 18 months in APOE4 noncarriers in 4 trials (ClinicalTrials.govidentifiers lNCT00575055, NCT00574132, NCT00676143, NCT00667810).Trials were halted after completion of 2 trials demonstrated a failure to meet primary outcome measures on ADAS-cog and activities of daily living.109 Solanezumab, humanized monoclonal antibody directed at amino acids 16-24 of Ab peptide.Amyloid plaque clearance mediated via peripheral sink mechanism.52 mild-moderate AD patients were randomized to placebo, 100mg every 4 weeks, 100mg weekly, 400mg every 4 weeks, 400mg weekly i.v.solanezumab for 12 weeks.There was a significant dose-dependent increase in Ab42 peptide in CSF.132 2,000 mild-moderate AD patients randomized to placebo and 400mg solanezumab monthly i.v. for 18 months (ClinicalTrials.govidentifiers NCT00905372, NCT00904683).Trials failed to meet their primary outcome measures on ADAS-cog and ADCS-ADL.A secondary analysis of mild AD patients pooled from both trials showed a significant effect on cognition.115 Gammagard, intravenous immunoglobulin.55 mild-moderate AD patients randomized to placebo, 0.2, 0.5, 0.8g/kg/4 weeks, or 0.1, 0.25, 0.4g/kg/2 weeks for 24 weeks.There was no increase in Ab40 peptide in plasma at any dose.129 Trial data currently unpublished.390 mild-moderate AD patients randomized to 0.2g/kg/2 weeks and 0.4g/kg/2 weeks vs placebo for 18 months (ClinicalTrials.govIdentifier NCT00818662).Gammagard failed to reach its coprimary outcomes of ADAS-cog and ADCS-ADL.AD 5 Alzheimer disease; ADAS-cog 5 Alzheimer's Disease Assessment Scale-Cognitive Subscale; ADCS-ADL 5 Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory; b.i.d. 5 twice daily; CDR-SB 5 Clinical Dementia Rating-Sum of Boxes; CSF 5 cerebrospinal fluid; i.v. 5 intravenous; o.d. 5 once per day.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Self-citationImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 1×
“The same purified preparations were also shown to inhibit Ab-mediated toxicity in fetal rat primary hippocampal cells, but the interpretation of direct Ab-mediated toxicity assays is challenging.(9) Other workers also demonstrated an antiaggregatory effect of affinitypurified anti-Ab antibodies on Ab-induced toxicity,…”
BackgroundSelf-citationA presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain
De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., et al. (1999) · Nature · doi:10.1038/19083 · Cited by 2,100
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 1×
“5-month-old PDAPP mice were treated with weekly injections of 3D6 for 6 months, the Ab burden (percentage of a brain section of the frontal cortex that can be immunohistochemically stained for Ab) was reduced by 86%.(96) However, it is unclear whether this regime reduced Ab levels to below those present at the start o…”
MethodTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 3×
“AD patients randomized to placebo and bapineuzumab.(109) Two separate trials were conducted in APOE4”
BackgroundMethodWolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., & Selkoe, D. J. (1999) · Nature · doi:10.1038/19077 · Cited by 1,916
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,498
Self-citationNeuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Wada, K., Tanaka, K., & Nakashima, K. (2011) · PubMed · Cited by 1,132
Age, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900
Ott, A., Breteler, M. M. B., van Harskamp, F., Claus, J. J., van der Cammen, T. J. M., Grobbee, D. E., & Hofman, A. (1995) · BMJ · doi:10.1136/bmj.310.6985.970 · Cited by 792
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660
NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18162 · Cited by 634
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
γ-Secretase: proteasome of the membrane?
Kopan, R., & Ilagan, M. X. G. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1406 · Cited by 554
(1997) · doi:10.1073/pnas.94.4.1550 · Cited by 535
The mechanism of γ‐Secretase dysfunction in familial Alzheimer disease
Chávez‐Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.79 · Cited by 495 · cited 1×
“The most informative study was performed using a cellfree, quantitative c-secretase in vitro assay where Notch and APP substrate concentrations were accurately controlled.(59) This demonstrated an Ab/Notch ratio of 0.”
MethodSelf-citationFerrer, I., Rovira, M. B., Guerra, M. L. S., Rey, M. J., & Costa‐Jussá, F. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00493.x · Cited by 479
Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process
De Strooper, B. (2010) · Physiological Reviews · doi:10.1152/physrev.00023.2009 · Cited by 455
A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
DeMattos, R. B., Lu, J., Tang, Y., Racke, M. M., DeLong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.10.029 · Cited by 442 · cited 1×
“3D6 is a mouse IgG2b antibody with an affinity for soluble Ab of <30nM(96) and between 3 and 5nM.(97) The dissociation constant (Kd) of the bapineuzumab Fab fragment for Ab1–40 was recently reported to be 89nM.”
BackgroundDisaggregation of Alzheimer β-amyloid by site-directed mAb
Solomon, B., Koppel, R., Frankel, D., & Hanan-Aharon, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4109 · Cited by 421
Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease
Masliah, E., Hansen, L., Adame, A., Crews, L., Bard, F., Lee, C., Seubert, P., Games, D., Kirby, L., & Schenk, D. (2005) · Neurology · doi:10.1212/01.wnl.0000148590.39911.df · Cited by 353
Fleisher, A. S., Raman, R., Siemers, E. R., Becerra, L., Clark, C. M., Dean, R. A., Farlow, M. R., Galvin, J. E., Peskind, E. R., Quinn, J. F., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1031 · Cited by 332
Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy
Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Games, D., Seubert, P., Schenk, D., & Hyman, B. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-18-07873.2002 · Cited by 323
A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system
Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., DeMattos, R. B., May, P. C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21623 · Cited by 322
Racke, M. M., Boone, L. I., Hepburn, D. L., Parsadainian, M., Bryan, M. T., Ness, D. K., Piroozi, K. S., Jordan, W. H., Brown, D. D., Hoffman, W. P., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4337-04.2005 · Cited by 320
Dodel, R. C. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.033399 · Cited by 317
Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis
Gervais, F., Paquette, J., Morissette, C., Krzywkowski, P., Yu, M., Azzi, M., Lacombe, D., Kong, X., Aman, A., Laurin, J., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.015 · Cited by 307
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Relkin, N. R., Szabo, P., Adamiak, B., Burgut, T., Monthe, C., Lent, R. W., Younkin, S., Younkin, L., Schiff, R., & Weksler, M. E. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.021 · Cited by 305
Snow, A. D., Sekiguchi, R., Nochlin, D., Fraser, P., Kimata, K., Mizutani, A., Arai, M., Schreier, W. A., & Morgan, D. G. (1994) · Neuron · doi:10.1016/0896-6273(94)90165-1 · Cited by 299
Jaturapatporn, D., Isaac, M. G. E. K. N., McCleery, J., & Tabet, N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006378.pub2 · Cited by 299
Aisen, P. S., Gauthier, S., Ferris, S. H., Saumier, D., Haine, D., Garceau, D., Duong, A., Suhy, J., Oh, J., Lau, W. C., et al. (2011) · Archives of Medical Science · doi:10.5114/aoms.2011.20612 · Cited by 295
Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease
Siemers, E. R., Quinn, J. F., Kaye, J., Farlow, M. R., Porsteinsson, A., Tariot, P., Zoulnouni, P., Galvin, J. E., Holtzman, D. M., Knopman, D. S., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000198762.41312.e1 · Cited by 295
Wilcock, G. K., Black, S. E., Hendrix, S. B., Zavitz, K. H., Swabb, E. A., & Laughlin, M. A. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70090-5 · Cited by 290
Substrate-targeting γ-secretase modulators
Kukar, T. L., Ladd, T. B., Bann, M. A., Fraering, P. C., Narlawar, R., Maharvi, G. M., Healy, B., Chapman, R., Welzel, A. T., Price, R. W., et al. (2008) · Nature · doi:10.1038/nature07055 · Cited by 280
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease
Farlow, M., Arnold, S. E., van Dyck, C. H., Aisen, P. S., Snider, B. J., Porsteinsson, A. P., Friedrich, S., Dean, R. A., Gonzales, C., Sethuraman, G., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.09.224 · Cited by 280
Inflammatory components in human Alzheimer’s disease and after active amyloid-β42 immunization
Zotova, E., Bharambe, V., Cheaveau, M., Morgan, W., Holmes, C., Harris, S., Neal, J. W., Love, S., Nicoll, J. A. R., & Boche, D. (2013) · Brain · doi:10.1093/brain/awt210 · Cited by 272
Characterizing the Appearance and Growth of Amyloid Plaques in APP/PS1 Mice
Yan, P., Bero, A. W., Cirrito, J. R., Xiao, Q., Hu, X., Wang, Y., Gonzales, E., Holtzman, D. M., & Lee, J.-M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2637-09.2009 · Cited by 264
DeMattos, R. B., Bales, K. R., Parsadanian, M., O'Dell, M. A., Foss, E. M., Paul, S. M., & Holtzman, D. M. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00889.x · Cited by 258
Mitchell, T. W., Mufson, E. J., Schneider, J. A., Cochran, E. J., Nissanov, J., Han, L., Bienias, J. L., Lee, V. M. ‐., Trojanowski, J. Q., Bennett, D. A., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10086 · Cited by 253
Reduced levels of amyloid β-peptide antibody in Alzheimer disease
Du, Y., Dodel, R., Hampel, H., Buerger, K., Lin, S., Eastwood, B., Bales, K., Gao, F., Moeller, H. –., Oertel, W., et al. (2001) · Neurology · doi:10.1212/wnl.57.5.801 · Cited by 235
Zetterberg, H. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.90 · Cited by 234
Mc Donald, J. M., Savva, G. M., Brayne, C., Welzel, A. T., Forster, G., Shankar, G. M., Selkoe, D. J., Ince, P. G., & Walsh, D. M. (2010) · Brain · doi:10.1093/brain/awq065 · Cited by 234
Cell death mechanisms in Parkinson's disease
Jellinger, K. A. (2000) · Journal of Neural Transmission · doi:10.1007/s007020050001 · Cited by 226
Castillo, G. M., Lukito, W., Wight, T. N., & Snow, A. D. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.721681.x · Cited by 223
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later
Roe, C. M., Fagan, A. M., Grant, E. A., Hassenstab, J., Moulder, K. L., Maue Dreyfus, D., Sutphen, C. L., Benzinger, T. L. S., Mintun, M. A., Holtzman, D. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182918ca6 · Cited by 222
Siemers, E., Skinner, M., Dean, R. A., Gonzales, C., Satterwhite, J., Farlow, M., Ness, D., & May, P. C. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000167360.27670.29 · Cited by 216
Mitani, Y., Yarimizu, J., Saita, K., Uchino, H., Akashiba, H., Shitaka, Y., Ni, K., & Matsuoka, N. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4264-11.2012 · Cited by 203
A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease
Aisen, P. S., Saumier, D., Briand, R., Laurin, J., Gervais, F., Tremblay, P., & Garceau, D. (2006) · Neurology · doi:10.1212/01.wnl.0000244346.08950.64 · Cited by 201
Amyloid-β Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients
Patton, R. L., Kalback, W. M., Esh, C. L., Kokjohn, T. A., Van Vickle, G. D., Luehrs, D. C., Kuo, Y.-M., Lopez, J., Brune, D., Ferrer, I., et al. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.060269 · Cited by 192
Siemers, E. R., Friedrich, S., Dean, R. A., Gonzales, C. R., Farlow, M. R., Paul, S. M., & DeMattos, R. B. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cb577a · Cited by 192
Dodel, R., Rominger, A., Bartenstein, P., Barkhof, F., Blennow, K., Förster, S., Winter, Y., Bach, J.-P., Popp, J., Alferink, J., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70014-0 · Cited by 187
Gillman, K. W., Starrett, J. E., Parker, M. F., Xie, K., Bronson, J. J., Marcin, L. R., McElhone, K. E., Bergstrom, C. P., Mate, R. A., Williams, R., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1000239 · Cited by 185
Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort
Breitner, J. C. S., Haneuse, S. J. P. A., Walker, R., Dublin, S., Crane, P. K., Gray, S. L., & Larson, E. B. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a18691 · Cited by 179
Martone, R. L., Zhou, H., Atchison, K. P., Comery, T. A., Xu, J. Z., Huang, X., Gong, X., Jin, M., Kreft, A. F., Harrison, B. L., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.152975 · Cited by 179
Beher, D., Clarke, E. E., Wrigley, J. D. J., Martin, A. C. L., Nadin, A., Churcher, I., & Shearman, M. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404937200 · Cited by 177
A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease
Black, R. S., Sperling, R. A., Safirstein, B., Motter, R. N., Pallay, A., Nichols, A., & Grundman, M. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181c53b00 · Cited by 170
Henley, D. B., May, P. C., Dean, R. A., & Siemers, E. R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903044982 · Cited by 168
Siemers, E., Dean, R. A., Friedrich, S. W., Ferguson‐Sells, L. R., Gonzales, C., Farlow, M. R., & May, P. C. (2007) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31805b7660 · Cited by 168
Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease
Dodel, R., Hampel, H., Depboylu, C., Lin, S., Gao, F., Schock, S., Jäckel, S., Wei, X., Buerger, K., Höft, C., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10253 · Cited by 161
Serrano-Pozo, A., William, C. M., Ferrer, I., Uro-Coste, E., Delisle, M.-B., Maurage, C.-A., Hock, C., Nitsch, R. M., Masliah, E., Growdon, J. H., et al. (2010) · Brain · doi:10.1093/brain/awq056 · Cited by 159
Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodies
Lee, M., Bard, F., Johnson‐Wood, K., Lee, C., Hu, K., Griffith, S. G., Black, R. S., Schenk, D., & Seubert, P. A. (2005) · Annals of Neurology · doi:10.1002/ana.20592 · Cited by 154
Secretase inhibitors and modulators for Alzheimer’s disease treatment
Tomita, T. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.24 · Cited by 154
NSAIDs and incident Alzheimer’s disease. The Rotterdam study
In ’t Veld, B. A., Launer, L. J., Hoes, A. W., Ott, A., Hofman, A., Breteler, M. M. B., & Stricker, B. H. C. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00096-7 · Cited by 145
Kukar, T. L., Prescott, S., Eriksen, J. L., Holloway, V. M., Murphy, M. P., Koo, E. H., Golde, T. E., & Nicolle, M. M. (2007) · BMC Neuroscience · doi:10.1186/1471-2202-8-54 · Cited by 144
γ‐Secretase inhibitors and modulators for Alzheimer’s disease
Wolfe, M. S. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07501.x · Cited by 139
Du, Y., Wei, X., Dodel, R., Sommer, N., Hampel, H., Gao, F., Ma, Z., Zhao, L., Oertel, W. H., & Farlow, M. (2003) · Brain · doi:10.1093/brain/awg191 · Cited by 138
Immunotherapy Reduces Vascular Amyloid- in PDAPP Mice
Schroeter, S., Khan, K., Barbour, R., Doan, M., Chen, M., Guido, T., Gill, D., Basi, G., Schenk, D., Seubert, P., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.2377-07.2008 · Cited by 133 · cited 1×
“1mg/kg; treatments administered weekly for 6 months), it was demonstrated that although 3D6 increased the incidence of microhemorrhage, this could be ameliorated at lower doses.(103) In addition, it was demonstrated that 3D6 treatment removed vascular amyloid and potentially prevented deposition.”
BackgroundGalasko, D. R., Graff‐Radford, N. R., May, S. J., Hendrix, S. B., Cottrell, B. A., Sagi, S. A., MATHER, G. G., Laughlin, M. A., Zavitz, K. H., Swabb, E. A., et al. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31815d1048 · Cited by 131
Miles, L. A., Crespi, G. A. N., Doughty, L., & Parker, M. W. (2013) · Scientific Reports · doi:10.1038/srep01302 · Cited by 130
Lanz, T. A., Karmilowicz, M. J., Wood, K. M., Pozdnyakov, N., Du, P., Piotrowski, M. A., Brown, T. M., Nolan, C. E., Richter, K. E. G., Finley, J. E., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110700 · Cited by 130
Pride, M. W., Seubert, P. A., Grundman, M., Hagen, M., Eldridge, J. H., & Black, R. S. (2008) · Neurodegenerative Diseases · doi:10.1159/000113700 · Cited by 128
Fukuyama, R., Mizuno, T., Mizuno, T., Mori, S., Nakajima, K., Fushiki, S., & Yanagisawa, K. (2000) · European Neurology · doi:10.1159/000008156 · Cited by 128
Antiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road?
Karran, E., & Hardy, J. (2014) · New England Journal of Medicine · doi:10.1056/nejme1313943 · Cited by 126 · cited 3×
“The latest trials of bapineuzumab and solanezumab provide tantalizing clues with respect to biomarker changes and clinical efficacy that remain challenging to interpret.(116) The field also awaits with great interest the progress of the phase 3 trials of MK-8931, a Beta-amyloid cleaving enzyme inhibitor that will inhi…”
BackgroundSelf-citationRelation of NSAIDs to incident AD, change in cognitive function, and AD pathology
Arvanitakis, Z., Grodstein, F., Bienias, J. L., Schneider, J. A., Wilson, R. S., Kelly, J. F., Evans, D. A., & Bennett, D. A. (2008) · Neurology · doi:10.1212/01.wnl.0000313813.48505.86 · Cited by 122
Microglial alterations in human Alzheimer's disease following Aβ42 immunization
Zotova, E., Holmes, C., Johnston, D. A., Neal, J., Nicoll, J. A. R., & Boche, D. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01156.x · Cited by 120
Peretto, I., Redaelli, S., Parini, C., Zandi, M., Raveglia, L. F., Dondio, G. M., Fontanella, L., Misiano, P., Bigogno, C., Rizzi, A., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0502541 · Cited by 111
Magga, J. M., Puli, L., Pihlaja, R., Kanninen, K. M., Neulamaa, S., Malm, T., Härtig, W., Grosche, J., Goldsteins, G., Tanila, H., et al. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-90 · Cited by 111
Effect of Different Anti-Aβ Antibodies on Aβ Fibrillogenesis as Assessed by Atomic Force Microscopy
Legleiter, J. A., Czilli, D. L., Gitter, B. D., Demattos, R. B., Holtzman, D. M., & Kowalewski, T. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.11.019 · Cited by 107
Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease
Imbimbo, B. P., Ottonello, S., Frisardi, V., Solfrizzi, V., Greco, A., Seripa, D., Pilotto, A., & Panza, F. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.11.93 · Cited by 105
Abramowski, D., Wiederhold, K.-H., Furrer, U., Jaton, A.-L., Neuenschwander, A., Runser, M.-J., Danner, S., Reichwald, J., Ammaturo, D., Staab, D., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.140327 · Cited by 89
Human antibodies reactive with beta-amyloid protein in Alzheimer's disease.
Gaskin, F., Finley, J., Fang, Q., Xu, S., & Fu, S. M. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.177.4.1181 · Cited by 88
Diagnostic and Therapeutic Potential of Amyloid-Reactive IgG Antibodies Contained in Human Sera
O’Nuallain, B., Hrncic, R., Wall, J. S., Weiss, D. T., & Solomon, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.7071 · Cited by 84
Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy.
Gervais, F., Chalifour, R. J., Garceau, D., Kong, X., Laurin, J., McLaughlin, R. W., Morissette, C., & Paquette, J. (2001) · PubMed · Cited by 83
IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders
Fillit, H. M., Hess, G. P., Hill, J. W., Bonnet, P., & Toso, C. (2009) · Neurology · doi:10.1212/wnl.0b013e3181ae7aaf · Cited by 80
Borgegård, T., Juréus, A., Olsson, F., Rosqvist, S., Sabirsh, A., Rotticci, D., Paulsen, K., Klintenberg, R., Yan, H., Waldman, M., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.305227 · Cited by 75
Stopping Alzheimer's Before It Starts
Miller, G. (2012) · Science · doi:10.1126/science.337.6096.790 · Cited by 73
García-Alloza, M., Subramanian, M., Thyssen, D. H., Borrelli, L. A., Fauq, A. H., Das, P., Golde, T. E., Hyman, B. T., & Bacskai, B. J. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-19 · Cited by 71
Lanz, T. A., Fici, G. J., & Merchant, K. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073965 · Cited by 68
Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse
Seubert, P. A., Barbour, R., Khan, K., Motter, R. N., Tang, P., Kholodenko, D., Kling, K., Schenk, D., Johnson‐Wood, K., Schroeter, S., et al. (2008) · Neurodegenerative Diseases · doi:10.1159/000112834 · Cited by 68
Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice
Harhausen, D., Khojasteh, U., Stahel, P. F., Morgan, B. P., Nietfeld, W., Dirnagl, U., & Trendelenburg, G. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-15 · Cited by 64
The Amyloid-β Rise and γ-Secretase Inhibitor Potency Depend on the Level of Substrate Expression
Burton, C. R., Meredith, J. E., Barten, D. M., Goldstein, M. E., Krause, C., Kieras, C. J., Sisk, L. M., Iben, L. G., Polson, C. T., Thompson, M. W., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804175200 · Cited by 63
Sanfeliu, V., Elías, A. R., Figueras, D., Verdura, T., Gelabert, M. L., Pique, J., Torra, J. E., Esteve, N., & Nadal, M. J. N. (1993) · PubMed · Cited by 61
Simple In Vitro Assays to Identify Amyloid-β Aggregation Blockers for Alzheimer's Disease Therapy
Guo, J., Yu, S. Y., & McGeer, P. L. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1331 · Cited by 58
Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques
Sonnen, J. A., Larson, E. B., Walker, R. L., Haneuse, S., Crane, P. K., Gray, S. L., Breitner, J. C. S., & Montine, T. J. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f52db1 · Cited by 57
Bard, F., Fox, M., Friedrich, S. W., Seubert, P. A., Schenk, D., Kinney, G. G., & Yednock, T. A. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.07.022 · Cited by 47
Nonspecificity of Binding of γ-Secretase Modulators to the Amyloid Precursor Protein
Beel, A. J., Barrett, P. J., Schnier, P. D., Hitchcock, S. A., Bagal, D., Sanders, C. R., & Jordan, J. B. (2009) · Biochemistry · doi:10.1021/bi901839d · Cited by 47
The biochemical aftermath of anti-amyloid immunotherapy
Maarouf, C. L., Daugs, I. D., Kokjohn, T. A., Kalback, W. M., Patton, R., Luehrs, D. C., Masliah, E., Nicoll, J. A. R., Sabbagh, M. N., Beach, T. G., et al. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-39 · Cited by 45
In vitro and in vivo profiling of CHF5022 and CHF5074
Imbimbo, B. P., Giudice, E. D., Cenacchi, V., Volta, R., Villetti, G., Facchinetti, F., Riccardi, B., Puccini, P., Moretto, N., Grassi, F., et al. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2006.12.010 · Cited by 43
Xu, S., & Gaskin, F. (1997) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(96)01861-1 · Cited by 40
May, P. C., Yang, Z., Li, W., Hyslop, P. A., Siemers, E., & Boggs, L. N. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80220-3 · Cited by 39
Das, P., Verbeeck, C., Minter, L. M., Chakrabarty, P., Felsenstein, K. M., Kukar, T. L., Maharvi, G. M., Fauq, A. H., Osborne, B. A., & Golde, T. E. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-39 · Cited by 36
Brodney, M. A., Auperin, D. D., Becker, S. L., Bronk, B. S., Brown, T. M., Coffman, K. J., Finley, J. E., Hicks, C. D., Karmilowicz, M. J., Lanz, T. A., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.118 · Cited by 35
Bacher, M., Depboylu, C., Du, Y., Noelker, C., Oertel, W. H., Behr, T. M., Henriksen, G., Béhé, M. P., & Dodel, R. C. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.08.083 · Cited by 34
NESS, D. K., Boggs, L. N., Hepburn, D. L., Gitter, B. D., Long, G. G., May, P. C., Piroozi, K. S., Schafer, K. A., & Yang, Z. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80800-5 · Cited by 33
Martineau, E., de Guzman, J. M., Rodionova, L., Kong, X., Mayer, P., & Aman, A. M. (2010) · Journal of the American Society for Mass Spectrometry · doi:10.1016/j.jasms.2010.05.007 · Cited by 31
Gitter, B. D., Czilli, D. L., Li, W., Dieckman, D. K., Bender, M. H., Nissen, J. S., Mabry, T. E., Yin, T., Boggs, L. N., McClure, D. B., et al. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)81897-9 · Cited by 29
γ‐Secretase modulators do not induce Aβ‐rebound and accumulation of β‐C‐terminal fragment
Li, T., Huang, Y., Jin, S., Ye, L., Rong, N., Yang, X., Ding, Y., Cheng, Z., Zhang, J., Wan, Z., et al. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07560.x · Cited by 28
Probing and Trapping a Sensitive Conformation: Amyloid-β Fibrils, Oligomers, and Dimers
Fawver, J. N., Duong, K. T., Wise-Scira, O., Chapa, R. P., Schall, H. E., Coskuner‐Weber, O., Zhu, X., Colom, L. V., & Murray, I. V. J. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120880 · Cited by 26
NSAID-Based γ-Secretase Modulators Do Not Bind to the Amyloid-β Polypeptide
Barrett, P. J., Sanders, C. R., Kaufman, S. A., Michelsen, K., & Jordan, J. B. (2011) · Biochemistry · doi:10.1021/bi201371j · Cited by 23
Hyslop, P. A., May, P. C., Audia, J. E., et al. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80493-7 · Cited by 15
(1999) · doi:10.1002/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m
Cited by
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Self-citationAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Lane, C. A., Hardy, J., & Schott, J. M. (2018) · European Journal of Neurology · doi:10.1111/ene.13439 · Cited by 2,616
Self-citationSala Frigerio, C., Wolfs, L., Fattorelli, N., Thrupp, N., Voytyuk, I., Schmidt, I., Mancuso, R., Chen, W.-T., Woodbury, M. E., Srivastava, G., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.099 · Cited by 926
Self-citationMolecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
Metadata
- Authors
- Karran, E., & Hardy, J.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2014-07-02
- Volume
- 76
- Issue
- 2
- Pages
- 185-205
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1585083630
- Cited by
- 275
- References
- 135
- FWCI
- 20.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.